Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymopentin is a synthetic pentapeptide that mimics the active site of the naturally occurring thymic hormone thymopoietin. It acts as an immunomodulator by promoting the differentiation and maturation of thymic T cells and natural killer (NK) cells, enhancing T helper cell function, and regulating T cell subset proportions. Its mechanism involves increasing intracellular cyclic adenosine monophosphate levels and modulating immune responses. Clinically, it has been used in autoimmune diseases (such as rheumatoid arthritis), immunodeficiency disorders (including HIV infection), adjunctive cancer therapy (e.g., chronic lymphocytic leukemia, Sezary's syndrome), atopic dermatitis, hepatocellular carcinoma, and to restore immune competence in elderly surgical patients or those with immunosuppression due to chemotherapy or radiotherapy. Due to poor membrane permeability and rapid metabolism resulting in a short half-life (~30 seconds), repeated injections or intravenous infusions are required for therapeutic effect[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymopentin.